- Home
- CANF vs TLPH Comparison
CANF vs TLPH Comparison
Compare CANF & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CANF
- TLPH
- Stock Information
- Founded
- CANF 1994
- TLPH 2005
- Country
- CANF Israel
- TLPH United States
- Employees
- CANF N/A
- TLPH N/A
- Industry
- CANF Biotechnology: Pharmaceutical Preparations
- TLPH Biotechnology: Pharmaceutical Preparations
- Sector
- CANF Health Care
- TLPH Health Care
- Exchange
- CANF Nasdaq
- TLPH Nasdaq
- Market Cap
- CANF 9.6M
- TLPH 11.1M
- IPO Year
- CANF N/A
- TLPH 2011
- Fundamental
- Price
- CANF $0.65
- TLPH $0.94
- Analyst Decision
- CANF Strong Buy
- TLPH Strong Buy
- Analyst Count
- CANF 2
- TLPH 1
- Target Price
- CANF $14.50
- TLPH $6.00
- AVG Volume (30 Days)
- CANF 171.1K
- TLPH 4.3M
- Earning Date
- CANF 08-26-2025
- TLPH 11-12-2025
- Dividend Yield
- CANF N/A
- TLPH N/A
- EPS Growth
- CANF N/A
- TLPH N/A
- EPS
- CANF N/A
- TLPH N/A
- Revenue
- CANF $560,000.00
- TLPH $27,000.00
- Revenue This Year
- CANF $461.72
- TLPH N/A
- Revenue Next Year
- CANF N/A
- TLPH $14,533.26
- P/E Ratio
- CANF N/A
- TLPH N/A
- Revenue Growth
- CANF N/A
- TLPH N/A
- 52 Week Low
- CANF $0.63
- TLPH $0.38
- 52 Week High
- CANF $3.12
- TLPH $1.20
- Technical
- Relative Strength Index (RSI)
- CANF 35.47
- TLPH 75.75
- Support Level
- CANF $0.64
- TLPH $0.88
- Resistance Level
- CANF $0.68
- TLPH $1.20
- Average True Range (ATR)
- CANF 0.02
- TLPH 0.13
- MACD
- CANF 0.01
- TLPH 0.03
- Stochastic Oscillator
- CANF 41.25
- TLPH 62.70
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.